Relation entre la tolérance de l?évérolimus et la concentration sanguine résiduelle d?évérolimus pour le traitement du carcinome rénal avancé

Trial Profile

Relation entre la tolérance de l?évérolimus et la concentration sanguine résiduelle d?évérolimus pour le traitement du carcinome rénal avancé

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms PEVERENAL
  • Most Recent Events

    • 17 Oct 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database.
    • 21 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top